PubMed@dpavot:32965395_en_relations
Annnotations
ENG_RE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 44-48 | CHEBI_50906 | denotes | role |
| T1 | 56-63 | DOID_4 | denotes | disease |
| T2 | 64-72 | HP_0012824 | denotes | severity |
| T3 | 90-98 | DOID_0080600 | denotes | COVID-19 |
| T4 | 267-278 | CHEBI_64360 | denotes | tocilizumab |
| T5 | 404-412 | DOID_0080600 | denotes | COVID-19 |
| T6 | 503-514 | CHEBI_64360 | denotes | tocilizumab |
| T7 | 584-592 | HP_0012826 | denotes | moderate |
| T8 | 596-602 | HP_0012828 | denotes | severe |
| T9 | 603-611 | DOID_0080600 | denotes | COVID-19 |
| T10 | 736-744 | CHEBI_82594 | denotes | ferritin |
| T11 | 761-768 | CHEBI_24996 | denotes | lactate |
| T12 | 930-938 | DOID_0080600 | denotes | COVID-19 |
| T13 | 1163-1170 | HP_0030645 | denotes | central |
| T14 | 1562-1583 | GO_0006954 | denotes | inflammatory response |
| T15 | 1587-1595 | DOID_0080600 | denotes | COVID-19 |
| R0 | T14 | T2 | no_relation | inflammatory response,severity |
| R1 | T14 | T7 | no_relation | inflammatory response,moderate |
| R2 | T14 | T8 | no_relation | inflammatory response,severe |
| R3 | T1 | T0 | effect | disease,role |
| R4 | T1 | T4 | effect | disease,tocilizumab |
| R5 | T1 | T6 | effect | disease,tocilizumab |
| R6 | T1 | T10 | effect | disease,ferritin |
| R7 | T1 | T11 | effect | disease,lactate |
| R8 | T3 | T0 | no_relation | COVID-19,role |
| R9 | T3 | T4 | effect | COVID-19,tocilizumab |
| R10 | T3 | T6 | effect | COVID-19,tocilizumab |
| R11 | T3 | T10 | effect | COVID-19,ferritin |
| R12 | T3 | T11 | effect | COVID-19,lactate |
| R13 | T5 | T0 | no_relation | COVID-19,role |
| R14 | T5 | T4 | effect | COVID-19,tocilizumab |
| R15 | T5 | T6 | effect | COVID-19,tocilizumab |
| R16 | T5 | T10 | effect | COVID-19,ferritin |
| R17 | T5 | T11 | effect | COVID-19,lactate |
| R18 | T9 | T0 | no_relation | COVID-19,role |
| R19 | T9 | T4 | effect | COVID-19,tocilizumab |
| R20 | T9 | T6 | effect | COVID-19,tocilizumab |
| R21 | T9 | T10 | effect | COVID-19,ferritin |
| R22 | T9 | T11 | effect | COVID-19,lactate |
| R23 | T12 | T0 | no_relation | COVID-19,role |
| R24 | T12 | T4 | effect | COVID-19,tocilizumab |
| R25 | T12 | T6 | no_relation | COVID-19,tocilizumab |
| R26 | T12 | T10 | no_relation | COVID-19,ferritin |
| R27 | T12 | T11 | no_relation | COVID-19,lactate |
| R28 | T15 | T0 | no_relation | COVID-19,role |
| R29 | T15 | T4 | effect | COVID-19,tocilizumab |
| R30 | T15 | T6 | no_relation | COVID-19,tocilizumab |
| R31 | T15 | T10 | no_relation | COVID-19,ferritin |
| R32 | T15 | T11 | no_relation | COVID-19,lactate |
ENG_RE_Diana
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 44-48 | CHEBI_50906 | denotes | role |
| T1 | 56-63 | DOID_4 | denotes | disease |
| T2 | 64-72 | HP_0012824 | denotes | severity |
| T3 | 90-98 | DOID_0080600 | denotes | COVID-19 |
| T4 | 267-278 | CHEBI_64360 | denotes | tocilizumab |
| T5 | 404-412 | DOID_0080600 | denotes | COVID-19 |
| T6 | 503-514 | CHEBI_64360 | denotes | tocilizumab |
| T7 | 584-592 | HP_0012826 | denotes | moderate |
| T8 | 596-602 | HP_0012828 | denotes | severe |
| T9 | 603-611 | DOID_0080600 | denotes | COVID-19 |
| T10 | 736-744 | CHEBI_82594 | denotes | ferritin |
| T11 | 761-768 | CHEBI_24996 | denotes | lactate |
| T12 | 930-938 | DOID_0080600 | denotes | COVID-19 |
| T13 | 1163-1170 | HP_0030645 | denotes | central |
| T14 | 1562-1583 | GO_0006954 | denotes | inflammatory response |
| T15 | 1587-1595 | DOID_0080600 | denotes | COVID-19 |
| R0 | T14 | T2 | no_relation | inflammatory response,severity |
| R1 | T14 | T7 | no_relation | inflammatory response,moderate |
| R2 | T14 | T8 | no_relation | inflammatory response,severe |
| R3 | T1 | T0 | effect | disease,role |
| R4 | T1 | T4 | effect | disease,tocilizumab |
| R5 | T1 | T6 | effect | disease,tocilizumab |
| R6 | T1 | T10 | effect | disease,ferritin |
| R7 | T1 | T11 | effect | disease,lactate |
| R8 | T3 | T0 | no_relation | COVID-19,role |
| R9 | T3 | T4 | effect | COVID-19,tocilizumab |
| R10 | T3 | T6 | effect | COVID-19,tocilizumab |
| R11 | T3 | T10 | effect | COVID-19,ferritin |
| R12 | T3 | T11 | effect | COVID-19,lactate |
| R13 | T5 | T0 | no_relation | COVID-19,role |
| R14 | T5 | T4 | effect | COVID-19,tocilizumab |
| R15 | T5 | T6 | effect | COVID-19,tocilizumab |
| R16 | T5 | T10 | effect | COVID-19,ferritin |
| R17 | T5 | T11 | effect | COVID-19,lactate |
| R18 | T9 | T0 | no_relation | COVID-19,role |
| R19 | T9 | T4 | effect | COVID-19,tocilizumab |
| R20 | T9 | T6 | effect | COVID-19,tocilizumab |
| R21 | T9 | T10 | effect | COVID-19,ferritin |
| R22 | T9 | T11 | effect | COVID-19,lactate |
| R23 | T12 | T0 | no_relation | COVID-19,role |
| R24 | T12 | T4 | effect | COVID-19,tocilizumab |
| R25 | T12 | T6 | no_relation | COVID-19,tocilizumab |
| R26 | T12 | T10 | no_relation | COVID-19,ferritin |
| R27 | T12 | T11 | no_relation | COVID-19,lactate |
| R28 | T15 | T0 | no_relation | COVID-19,role |
| R29 | T15 | T4 | effect | COVID-19,tocilizumab |
| R30 | T15 | T6 | no_relation | COVID-19,tocilizumab |
| R31 | T15 | T10 | no_relation | COVID-19,ferritin |
| R32 | T15 | T11 | no_relation | COVID-19,lactate |
ENG_RE_pruas
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 44-48 | CHEBI_50906 | denotes | role |
| T1 | 56-63 | DOID_4 | denotes | disease |
| T10 | 736-744 | CHEBI_82594 | denotes | ferritin |
| T11 | 761-768 | CHEBI_24996 | denotes | lactate |
| T12 | 930-938 | DOID_0080600 | denotes | COVID-19 |
| T13 | 1163-1170 | HP_0030645 | denotes | central |
| T14 | 1562-1583 | GO_0006954 | denotes | inflammatory response |
| T15 | 1587-1595 | DOID_0080600 | denotes | COVID-19 |
| T2 | 64-72 | HP_0012824 | denotes | severity |
| T3 | 90-98 | DOID_0080600 | denotes | COVID-19 |
| T4 | 267-278 | CHEBI_64360 | denotes | tocilizumab |
| T5 | 404-412 | DOID_0080600 | denotes | COVID-19 |
| T6 | 503-514 | CHEBI_64360 | denotes | tocilizumab |
| T7 | 584-592 | HP_0012826 | denotes | moderate |
| T8 | 596-602 | HP_0012828 | denotes | severe |
| T9 | 603-611 | DOID_0080600 | denotes | COVID-19 |
| T16 | 106-133 | CHEBI_67079 | denotes | anti-inflammatory therapies |
| T17 | 186-219 | GO_0002526 | denotes | uncontrolled inflammatory cascade |
| T18 | 90-98 | HP_0033141 | denotes | COVID-19 |
| T19 | 404-412 | HP_0033141 | denotes | COVID-19 |
| T20 | 603-611 | HP_0033141 | denotes | COVID-19 |
| T21 | 930-938 | HP_0033141 | denotes | COVID-19 |
| T22 | 1587-1595 | HP_0033141 | denotes | COVID-19 |
| R2 | T14 | T8 | no_relation | inflammatory response,severe |
| R20 | T9 | T6 | effect | COVID-19,tocilizumab |
| R21 | T9 | T10 | effect | COVID-19,ferritin |
| R22 | T9 | T11 | effect | COVID-19,lactate |
| R23 | T12 | T0 | no_relation | COVID-19,role |
| R24 | T12 | T4 | effect | COVID-19,tocilizumab |
| R25 | T12 | T6 | no_relation | COVID-19,tocilizumab |
| R26 | T12 | T10 | no_relation | COVID-19,ferritin |
| R27 | T12 | T11 | no_relation | COVID-19,lactate |
| R28 | T15 | T0 | no_relation | COVID-19,role |
| R29 | T15 | T4 | effect | COVID-19,tocilizumab |
| R30 | T15 | T6 | no_relation | COVID-19,tocilizumab |
| R31 | T15 | T10 | no_relation | COVID-19,ferritin |
| R32 | T15 | T11 | no_relation | COVID-19,lactate |
| R4 | T1 | T4 | effect | disease,tocilizumab |
| R5 | T1 | T6 | effect | disease,tocilizumab |
| R6 | T1 | T10 | effect | disease,ferritin |
| R7 | T1 | T11 | effect | disease,lactate |
| R8 | T3 | T0 | no_relation | COVID-19,role |
| R9 | T3 | T4 | effect | COVID-19,tocilizumab |
| R33 | T16 | T17 | effect | anti-inflammatory therapies,uncontrolled inflammatory cascade |
| R34 | T8 | T20 | effect | severe,COVID-19 |
| R35 | T7 | T20 | effect | moderate,COVID-19 |
| R36 | T7 | T9 | effect | moderate,COVID-19 |
| R37 | T8 | T9 | effect | severe,COVID-19 |
| R38 | T22 | T14 | effect | COVID-19,inflammatory response |
| R39 | T15 | T14 | effect | COVID-19,inflammatory response |
| R0 | T14 | T2 | no_relation | inflammatory response,severity |
| R1 | T14 | T7 | no_relation | inflammatory response,moderate |
| R10 | T3 | T6 | effect | COVID-19,tocilizumab |
| R11 | T3 | T10 | effect | COVID-19,ferritin |
| R12 | T3 | T11 | effect | COVID-19,lactate |
| R13 | T5 | T0 | no_relation | COVID-19,role |
| R14 | T5 | T4 | effect | COVID-19,tocilizumab |
| R15 | T5 | T6 | effect | COVID-19,tocilizumab |
| R16 | T5 | T10 | effect | COVID-19,ferritin |
| R17 | T5 | T11 | effect | COVID-19,lactate |
| R18 | T9 | T0 | no_relation | COVID-19,role |
| R19 | T9 | T4 | effect | COVID-19,tocilizumab |
RELASIGEBLAH7hhaider5
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 44-48 | CHEBI_50906 | denotes | role |
| T1 | 56-63 | DOID_4 | denotes | disease |
| T10 | 736-744 | CHEBI_82594 | denotes | ferritin |
| T12 | 930-938 | DOID_0080600 | denotes | COVID-19 |
| T13 | 1163-1170 | HP_0030645 | denotes | central |
| T14 | 1562-1583 | GO_0006954 | denotes | inflammatory response |
| T15 | 1587-1595 | DOID_0080600 | denotes | COVID-19 |
| T16 | 0-24 | DOID_0080600 | denotes | Pro-inflammatory markers |
| T2 | 64-72 | HP_0012824 | denotes | severity |
| T3 | 90-98 | DOID_0080600 | denotes | COVID-19 |
| T4 | 267-278 | CHEBI_64360 | denotes | tocilizumab |
| T5 | 404-412 | DOID_0080600 | denotes | COVID-19 |
| T6 | 503-514 | CHEBI_64360 | denotes | tocilizumab |
| T7 | 584-592 | HP_0012826 | denotes | moderate |
| T8 | 596-602 | HP_0012828 | denotes | severe |
| T9 | 603-611 | DOID_0080600 | denotes | COVID-19 |
| T17 | 685-692 | DOID_0080600 | denotes | D-dimer |
| T18 | 707-725 | DOID_0080600 | denotes | C reactive protein |
| T11 | 761-782 | CHEBI_24996 | denotes | lactate dehydrogenase |
| R0 | T14 | T2 | effect | inflammatory response,severity |
| R1 | T14 | T7 | effect | inflammatory response,moderate |
| R10 | T3 | T6 | negative | COVID-19,tocilizumab |
| R11 | T3 | T10 | effect | COVID-19,ferritin |
| R13 | T5 | T0 | no_relation | COVID-19,role |
| R14 | T5 | T4 | negative | COVID-19,tocilizumab |
| R15 | T5 | T6 | negative | COVID-19,tocilizumab |
| R16 | T5 | T10 | effect | COVID-19,ferritin |
| R18 | T9 | T0 | no_relation | COVID-19,role |
| R19 | T9 | T4 | negative | COVID-19,tocilizumab |
| R2 | T14 | T8 | effect | inflammatory response,severe |
| R20 | T9 | T6 | negative | COVID-19,tocilizumab |
| R21 | T9 | T10 | no_relation | COVID-19,ferritin |
| R23 | T12 | T0 | no_relation | COVID-19,role |
| R24 | T12 | T4 | negative | COVID-19,tocilizumab |
| R25 | T12 | T6 | negative | COVID-19,tocilizumab |
| R26 | T12 | T10 | effect | COVID-19,ferritin |
| R28 | T15 | T0 | no_relation | COVID-19,role |
| R29 | T15 | T4 | negative | COVID-19,tocilizumab |
| R3 | T1 | T0 | no_relation | disease,role |
| R30 | T15 | T6 | negative | COVID-19,tocilizumab |
| R31 | T15 | T10 | effect | COVID-19,ferritin |
| R33 | T16 | T3 | effect | Pro-inflammatory markers,COVID-19 |
| R34 | T4 | T3 | negative | tocilizumab,COVID-19 |
| R4 | T1 | T4 | negative | disease,tocilizumab |
| R5 | T1 | T6 | negative | disease,tocilizumab |
| R6 | T1 | T10 | effect | disease,ferritin |
| R8 | T3 | T0 | no_relation | COVID-19,role |
| R35 | T1 | T3 | effect | disease,COVID-19 |
| R7 | T1 | T11 | effect | disease,lactate dehydrogenase |
| R32 | T15 | T11 | effect | COVID-19,lactate dehydrogenase |
| R27 | T12 | T11 | effect | COVID-19,lactate dehydrogenase |
| R22 | T9 | T11 | effect | COVID-19,lactate dehydrogenase |
| R17 | T5 | T11 | effect | COVID-19,lactate dehydrogenase |
| R12 | T3 | T11 | effect | COVID-19,lactate dehydrogenase |
| R36 | T3 | T17 | effect | COVID-19,D-dimer |
| R37 | T3 | T18 | effect | COVID-19,C reactive protein |
ENG_RE_mabarros
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 44-48 | CHEBI_50906 | denotes | role |
| T1 | 56-63 | DOID_4 | denotes | disease |
| T10 | 736-744 | CHEBI_82594 | denotes | ferritin |
| T12 | 930-938 | DOID_0080600 | denotes | COVID-19 |
| T14 | 1562-1583 | GO_0006954 | denotes | inflammatory response |
| T15 | 1587-1595 | DOID_0080600 | denotes | COVID-19 |
| T2 | 64-72 | HP_0012824 | denotes | severity |
| T3 | 90-98 | DOID_0080600 | denotes | COVID-19 |
| T4 | 267-278 | CHEBI_64360 | denotes | tocilizumab |
| T5 | 404-412 | DOID_0080600 | denotes | COVID-19 |
| T6 | 503-514 | CHEBI_64360 | denotes | tocilizumab |
| T7 | 584-592 | HP_0012826 | denotes | moderate |
| T8 | 596-602 | HP_0012828 | denotes | severe |
| T9 | 603-611 | DOID_0080600 | denotes | COVID-19 |
| R0 | T14 | T2 | no_relation | inflammatory response,severity |
| R1 | T14 | T7 | no_relation | inflammatory response,moderate |
| R10 | T3 | T6 | effect | COVID-19,tocilizumab |
| R11 | T3 | T10 | effect | COVID-19,ferritin |
| R13 | T5 | T0 | no_relation | COVID-19,role |
| R14 | T5 | T4 | effect | COVID-19,tocilizumab |
| R15 | T5 | T6 | effect | COVID-19,tocilizumab |
| R16 | T5 | T10 | effect | COVID-19,ferritin |
| R18 | T9 | T0 | no_relation | COVID-19,role |
| R19 | T9 | T4 | effect | COVID-19,tocilizumab |
| R2 | T14 | T8 | no_relation | inflammatory response,severe |
| R20 | T9 | T6 | effect | COVID-19,tocilizumab |
| R21 | T9 | T10 | effect | COVID-19,ferritin |
| R23 | T12 | T0 | no_relation | COVID-19,role |
| R24 | T12 | T4 | effect | COVID-19,tocilizumab |
| R25 | T12 | T6 | no_relation | COVID-19,tocilizumab |
| R26 | T12 | T10 | no_relation | COVID-19,ferritin |
| R28 | T15 | T0 | no_relation | COVID-19,role |
| R29 | T15 | T4 | effect | COVID-19,tocilizumab |
| R30 | T15 | T6 | no_relation | COVID-19,tocilizumab |
| R31 | T15 | T10 | no_relation | COVID-19,ferritin |
| R4 | T1 | T4 | effect | disease,tocilizumab |
| R5 | T1 | T6 | effect | disease,tocilizumab |
| R6 | T1 | T10 | effect | disease,ferritin |
| R8 | T3 | T0 | no_relation | COVID-19,role |
| R9 | T3 | T4 | effect | COVID-19,tocilizumab |